Nanobiotix S.A. ADR NBTX 深 滬
等待開盤 10-27 09:30:00 美东时间
19.20
-0.080
-0.41%
華盛通- 最 高19.37
- 今 開19.15
- 成交量 17.69万股
- 最 低 18.081
- 昨 收 19.28
- 總市值 9.26亿
- 52周最高 30.35
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 2.76
- 委 比 -33.33%
- 總股本 4821.47万
- 歷史最高 30.35
- 量 比 1.52
- 振 幅 6.69%
- 歷史最低 1.75
- 每 手 1
- 風險率 5.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
Nanobiotix announced the completion of transferring sponsorship and operational control of the NANORAY-312 clinical trial for JNJ-1900 (NBTXR3) to Johnson & Johnson. Interim data analysis is expected in 1H2027 after recruitment and requisite events. Nanobiotix will continue to provide updates on its sponsored studies and collaborations. JNJ-1900, a novel oncology product, is activated by radiotherapy and has shown potential in treating solid tumo...
10-24 06:00
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-20 20:10
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on ...
10-08 22:39
Nanobiotix SA ADR Reports Revenue Surge Amid Strategic Advances
Nanobiotix Sa ADR ( ($NBTX) ) has released its Q2 earnings. Here is a breakdown...
10-04 11:50
Nanobiotix S.A. GAAP EPS of -€0.11, revenue of €26.6M
Nanobiotix S.A. press release (OTC:NNBXF): 1H GAAP EPS of -€0.11. Revenue of €26.6M. More on Nanobiotix Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case Nanobiotix S.A. (NBTX)...
10-01 22:07
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
NANOBIOTIX announced initial Phase 1 data for JNJ-1900 (NBTXR3) in locally advanced esophageal adenocarcinoma, showing an 85% disease control rate (DCR) and 69% objective response rate (ORR) in 13 patients. The treatment was well-tolerated with no grade 3+ adverse events related to the injection procedure. The study is ongoing with 17 additional patients being recruited. JNJ-1900, a radioenhancer, has shown promise in enhancing local tumor contro...
10-01 20:15
Nanobiotix Releases Half-Year Financial Report Highlighting JNJ-1900 Developments
Nanobiotix ( ($NBTX) ) just unveiled an announcement. On September 30, 2025, Na...
10-01 04:54
Nanobiotix H1 EPS $(0.12) Up From $(0.50) YoY, Sales $30.202M Up From $10.001M YoY
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.12) per share. This is a 76 percent increase over losses of $(0.50) per share from the same period last year. The company reported $30.202 million in sales this
10-01 04:36
Nanobiotix-J&J Therapy Shows Promise In Tough Head And Neck Cancer
Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and survival outcomes.
10-01 01:43
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
<p>NanoBiotix reported operational and financial updates for the first half of 2025. Key highlights include progress in clinical trials for JNJ-1900 (NBTXR3), reclassification from a medical device to a drug, and a new patent filing. Financially, revenue increased to €26.6 million, R&D expenses decreased, and net loss narrowed to €5.4 million. Despite cash reserves of €28.8 million, the company faces liquidity challenges and is exploring non-dilu...
09-30 20:15
